Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F9QH
|
|||
| Former ID |
DIB012354
|
|||
| Drug Name |
Abituzumab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 2 | [1] | |
| Company |
Emd serono
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann Oncol. 2015 Jan;26(1):132-40. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.